HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NPT200-11

small molecule alpha-synuclein misfolding inhibitor

Also Known As:

1-(3-(1H-Indol-3-yl)propanoyl)-6-butyl-8-(piperidin-4-ylmethyl)hexahydro-4H-pyrazino(1,2-a)pyrimidine-4,7(6H)-dione

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Bonhaus, Douglas: 1 article (11/2018)
2.	Khan, Asma: 1 article (11/2018)
3.	Koike, Maya A: 1 article (11/2018)
4.	Masliah, Eliezer: 1 article (11/2018)
5.	Price, Diana L: 1 article (11/2018)
6.	Rockenstein, Edward: 1 article (11/2018)
7.	Wrasidlo, Wolfgang: 1 article (11/2018)

Related Diseases

1.	Gliosis 11/01/2018 - "Results from these studies demonstrated that NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function. "
2.	Neuroinflammatory Diseases 11/01/2018 - "Results from these studies demonstrated that NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function. "
3.	Synucleinopathies 11/01/2018 - "Results from these studies demonstrated that NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function. "
4.	Parkinson Disease (Parkinson's Disease) 11/01/2018 - "The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease."

Related Drugs and Biologics

1.	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)
2.	alpha-Synuclein